Alkermes plc (ALKS)Officer sold ~$36K

~$36K

Approx. value · 700 sh @ $52.13

73K

Holds after · shares reported

Traded

Jul 1, 2026

Filed

Jul 1, 2026

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

1. Feb 24, 2026Company filing · Form 8-K · Executive changeChanged a top executive or board member“On July 28, 2026, the Board took action to expand Mr. Jackson’s responsibilities and, commensurate with such expansion, to also appoint Mr. Jackson as President of the Company, effective August 1, 2026, and to approve Mr. Jackson’s compensation arrangements for his role as President and CEO, in each case effective August 1, 2026.”
2. May 1, 2026InsiderOfficer sold ~$301K of ALKS shares in the open market
3. May 4, 2026InsiderOfficer sold ~$68K of ALKS shares in the open market
4. May 5, 2026Company filing · Form 8-K · ResultsReported its results
5. May 20, 2026Company filing · Form 8-K · Executive change, Shareholder voteChanged a top executive or board member, and held a shareholder vote“On May 20, 2026, at the 2026 annual general meeting of shareholders (the “Annual Meeting”) of Alkermes plc (the “Company”), the Company’s shareholders approved amendments to the Alkermes plc 2018 Stock Option and Incentive Plan to, among other things, increase the number of the Company’s ordinary shares authorized for issuance thereunder by 5,900,000 (the plan as so amended, the “2018 Plan”).”
6. May 29, 2026InsiderOfficer sold ~$687K of ALKS shares in the open market
7. Jun 1, 2026InsiderOfficer sold ~$375K of ALKS shares in the open market
8. Jun 4, 2026InsiderOfficer sold ~$88K of ALKS shares in the open market
9. Jun 12, 2026InsiderDirector sold ~$90K of ALKS shares in the open market
10. Jul 1, 2026 · this disclosureInsiderOfficer sold ~$36K of ALKS shares in the open market

What came next

1. Jul 1, 2026InsiderOfficer sold ~$427K of ALKS shares in the open market
2. Jul 6, 2026Company filing · Form 8-K · Agreement endedEnded an important agreement
3. Jul 6, 2026InsiderOfficer sold ~$110K of ALKS shares in the open market
4. Jul 28, 2026Company filing · Form 8-K · ResultsReported its results
5. Jul 30, 2026CongressDisclosed purchase of ALKS — reported range $15,001 - $50,000
6. Aug 3, 2026Insider · 3 peopleInsiders: 3 sales (~$2.8M)
7. Aug 12, 2026Company filing · Form 8-K · Material agreementSigned an important agreement
8. Aug 17, 2026Insider · 1 personInsiders: 2 sales (~$373K)
9. Sep 1, 2026InsiderOfficer sold ~$423K of ALKS shares in the open market
10. Sep 3, 2026InsiderOfficer sold ~$98K of ALKS shares in the open market
11. Sep 14, 2026Company filing · Form 8-K · Executive change, Reg FDChanged a top executive or board member, and shared information with investors“On September 14, 2026, the board of directors (the “Board”) of Alkermes plc (the “Company”) increased the size of the Board from ten (10) to eleven (11) directors and appointed Anne C. Whitaker to the Board, effective immediately, with an initial term expiring at the Company’s 2027 annual general meeting of shareholders.”
12. Oct 2, 2026InsiderOfficer sold ~$83K of ALKS shares in the open market

How to read SEC Form 4

Form 4 is the filing that officers, directors and owners of more than 10% of a US-listed company must send to the SEC within two business days after they buy, sell or otherwise change their holding of the company's stock.

Full guide: What is an SEC Form 4?

What else is on file for Alkermes plc

For Alkermes plc, OQRO holds 9 insider filings (SEC Form 4 or Form 144), 1 Congress trade report and 7 fund holdings reports (13F) dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its ALKS page.

Other recent filings by Craig C. Hopkinson, EVP R&D, Chief Medical Officer

• SEC Form 4 at Alkermes plc (ALKS)Sep 1, 2026
• SEC Form 4 at Alkermes plc (ALKS)Aug 3, 2026
• SEC Form 4 at Alkermes plc (ALKS)Jul 1, 2026
• SEC Form 4 at Alkermes plc (ALKS)Jun 1, 2026
• SEC Form 4 at Alkermes plc (ALKS)May 2, 2026

The full history of Craig C. Hopkinson, EVP R&D, Chief Medical Officer is on the profile page.

How this filing works

• SEC Form 4
• Open-market purchase
• Rule 10b5-1 trading plans

Other disclosures at Alkermes plc

• SEC Form 4Oct 2, 2026
• SEC Form 144Oct 2, 2026
• House Clerk periodic transaction reportSep 4, 2026
• SEC Form 4Sep 3, 2026
• SEC Form 4Sep 1, 2026
• SEC Form 4Aug 17, 2026

Everything OQRO holds on this company is on its ALKS page.